Accueil
A partir de cette page vous pouvez :
Retourner au premier écran avec les dernières notices... |
Résultat de la recherche
1 résultat(s) recherche sur le mot-clé 'immune evasion'
Affiner la recherche Faire une suggestion
IMMUNE EVASION OF MYCOPLASMA / AJI NARJISS
Titre : IMMUNE EVASION OF MYCOPLASMA Type de document : thèse Auteurs : AJI NARJISS, Auteur Année de publication : 2023 Langues : Anglais (eng) Mots-clés : Mycoplasma pneumoniae Ureaplasma urealyticum Mycoplasma hominis Mycoplasma genitalium Immune evasion Mycoplasma Pneumoniae Ureaplasma Urealyticum Mycoplasma Hominis Mycoplasma genitalium immune evasion مفطورة رئویة المی ورة الحا لة للیوریا ال مفطورة البشریة ال مفطورة التناسلیة التھرب
المناعيRésumé : Mycoplasmas are a group of bacteria that can cause a range of human diseases affecting various
body systems, including the respiratory, urogenital, musculoskeletal, central nervous, and
cardiovascular systems. Unlike other prokaryotes, mycoplasmas have a small genome and limited
biosynthetic capabilities. Moreover, they lack a cell wall and instead have a plasma membrane
composed of cholesterol and glycolipids. This characteristic enables them to evade the host's immune
response.
Mycoplasmas have virulence factors that allow them to invade and survive within host cells,
triggering inflammation and clinical manifestations. Once inside the host cell, mycoplasmas can lead
to cell death or dysfunction. This, in turn, elicits an inflammatory response, causing the clinical
manifestations of mycoplasma infections.
The treatment of mycoplasma infections depends on the specific bacterial species involved and
the severity of the infection. Antibiotics are typically used to treat these infections.
However, some mycoplasma species are resistant to traditional antibiotics, necessitating
alternative treatments. Macrolide antibiotics are commonly used as first-line treatments for
most mycoplasma infections, but other antibiotics may be necessary based on the resistance
profile of the bacteria.
Mycoplasmas have several mechanisms that enable them to evade the host immune response,
such as altering the composition of their cell membrane to prevent recognition by host immune cells,
secreting proteins that inhibit immune cell function, and inducing host cells to produce cytokines that
suppress the immune response. Hence, understanding their clinical manifestations, pathophysiology,
and treatment options is crucial for managing and preventing these infections.
In conclusion, mycoplasmas are a unique group of bacteria responsible of various human
diseases. Their ability to evade the host immune response and their resistance to traditional antibiotics
make their treatment challenging. However, by gaining a better understanding of their virulence
factors and mechanisms of immune evasion, we can develop more effective treatments for these
infections.
Numéro (Thèse ou Mémoire) : M3032023 Président : Yassine SEKHSOKH Directeur : Mimoun ZOUHDI Juge : Ahmed GAOUZI Juge : Mariama CHADLI IMMUNE EVASION OF MYCOPLASMA [thèse] / AJI NARJISS, Auteur . - 2023.
Langues : Anglais (eng)
Mots-clés : Mycoplasma pneumoniae Ureaplasma urealyticum Mycoplasma hominis Mycoplasma genitalium Immune evasion Mycoplasma Pneumoniae Ureaplasma Urealyticum Mycoplasma Hominis Mycoplasma genitalium immune evasion مفطورة رئویة المی ورة الحا لة للیوریا ال مفطورة البشریة ال مفطورة التناسلیة التھرب
المناعيRésumé : Mycoplasmas are a group of bacteria that can cause a range of human diseases affecting various
body systems, including the respiratory, urogenital, musculoskeletal, central nervous, and
cardiovascular systems. Unlike other prokaryotes, mycoplasmas have a small genome and limited
biosynthetic capabilities. Moreover, they lack a cell wall and instead have a plasma membrane
composed of cholesterol and glycolipids. This characteristic enables them to evade the host's immune
response.
Mycoplasmas have virulence factors that allow them to invade and survive within host cells,
triggering inflammation and clinical manifestations. Once inside the host cell, mycoplasmas can lead
to cell death or dysfunction. This, in turn, elicits an inflammatory response, causing the clinical
manifestations of mycoplasma infections.
The treatment of mycoplasma infections depends on the specific bacterial species involved and
the severity of the infection. Antibiotics are typically used to treat these infections.
However, some mycoplasma species are resistant to traditional antibiotics, necessitating
alternative treatments. Macrolide antibiotics are commonly used as first-line treatments for
most mycoplasma infections, but other antibiotics may be necessary based on the resistance
profile of the bacteria.
Mycoplasmas have several mechanisms that enable them to evade the host immune response,
such as altering the composition of their cell membrane to prevent recognition by host immune cells,
secreting proteins that inhibit immune cell function, and inducing host cells to produce cytokines that
suppress the immune response. Hence, understanding their clinical manifestations, pathophysiology,
and treatment options is crucial for managing and preventing these infections.
In conclusion, mycoplasmas are a unique group of bacteria responsible of various human
diseases. Their ability to evade the host immune response and their resistance to traditional antibiotics
make their treatment challenging. However, by gaining a better understanding of their virulence
factors and mechanisms of immune evasion, we can develop more effective treatments for these
infections.
Numéro (Thèse ou Mémoire) : M3032023 Président : Yassine SEKHSOKH Directeur : Mimoun ZOUHDI Juge : Ahmed GAOUZI Juge : Mariama CHADLI Réservation
Réserver ce document
Exemplaires
Code barre Cote Support Localisation Section Disponibilité M3032023 WA Thèse imprimé Unité des Thèses et Mémoires ThèsesMéd2023 Disponible